Glenmark Pharmaceuticals receives USFDA final approval for Abiraterone Acetate Tablets
Capital MarketGlenmark Pharmaceuticals has been
granted final approval by the United States Food & Drug Administration (U.S. FDA) for Abiraterone
Acetate Tablets USP, 250 mg, a generic version of Zytiga1 Tablets, 250 mg, of Janssen Biotech, Inc.
According to IQVIATM sales data for the 12 month period ending August 2019, the Zytiga Tablets,
250 mg market achieved annual sales of approximately $794.1 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
